CLDX
CLDX clinical trials: Celldex Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Celldex Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 69
- Trials linked
- 45
- As lead sponsor
- 24
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CLDX on the catalyst calendar · CLDX registry changes
- Primary completion Aug 4, 2026ActualPhase 3NCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Celldex Therapeutics · Chronic Spontaneous UrticariaActive, not recruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 12, 2026ActualPhase 3NCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaCelldex Therapeutics · Chronic Spontaneous UrticariaActive, not recruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07266402A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and...Celldex Therapeutics · Chronic Inducible UrticariaRecruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT07256392Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaCelldex Therapeutics · Chronic Spontaneous UrticariaEnrolling by invitationCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2026ActualPhase 2NCT06727552A Study of Barzolvolimab in Patients With Atopic DermatitisCelldex Therapeutics · Atopic DermatitisActive, not recruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2026ActualPhase 2NCT06366750A Study of Barzolvolimab in Patients With Prurigo NodularisCelldex Therapeutics · Prurigo NodularisActive, not recruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1NCT07330778A Study of CDX-622 in Participants With Mild to Moderate AsthmaCelldex Therapeutics · Mild to Moderate AsthmaRecruitingCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2025ActualPhase 2NCT05774184A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCelldex Therapeutics · Eosinophilic EsophagitisCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2026ActualPhase 1NCT06650761A Phase I Study of CDX-622Celldex Therapeutics · Healthy ParticipantsCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2024ActualPhase 2NCT05405660A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCelldex Therapeutics · Chronic Inducible UrticariaCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2025ActualPhase 1NCT05788484A Study of CDX-585 in Patients With Advanced MalignanciesCelldex Therapeutics · Non-small Cell Lung CancerCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2023ActualPhase 2NCT05368285A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCelldex Therapeutics · Chronic Spontaneous UrticariaCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2022ActualPhase 1NCT03329950A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex Therapeutics · MelanomaCompletedCLDXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2023ActualPhase 1NCT04944862A Study of CDX-0159 in Patients With Prurigo NodularisCelldex Therapeutics · Prurigo NodularisCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2023ActualPhase 1NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCelldex Therapeutics · Chronic Spontaneous UrticariaCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2023ActualPhase 1NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesCelldex Therapeutics · Non-small Cell Lung CancerCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2022ActualPhase 1NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria...Celldex Therapeutics · Cold UrticariaCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 16, 2020ActualPhase 2NCT03254927A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaCelldex Therapeutics · Advanced Head and Neck Squamous Cell CarcinomaTerminatedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2022ActualPhase 1NCT05031624A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCelldex Therapeutics · Healthy SubjectsCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2020ActualPhase 1NCT04146129A Phase 1 Study of CDX-0159Celldex Therapeutics · Healthy SubjectsCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2018ActualPhase 1NCT02837991A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaCelldex Therapeutics · Renal Cell Carcinoma (RCC)TerminatedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2015ActualPhase 2NCT01498328A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCelldex Therapeutics · GlioblastomaCompletedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2011ActualPhase 2NCT01094496A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)Celldex Therapeutics · Bladder CancerTerminatedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2018ActualPhase 1/Phase 2NCT02335918A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCelldex Therapeutics · Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedCLDXLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 14, 2018ActualPhase 2NCT02302339A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaCelldex Therapeutics · MelanomaTerminatedCLDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 44 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner